Licensees in research-based alliances often offset the cost of these deals by supplanting large cash payments or equity purchases with the exchange of a valuable, non-cash asset. We examine some of these "quid pro quo" alliances that have taken place over the last year.
You may also be interested in...
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.